Abstract: An object of the present invention is to improve the hardness of the capsule film of a hard capsule. The present invention improves the hardness of the capsule film of a hard capsule by adding a starch decomposition product, and/or at least one clay mineral selected from the group consisting of talc, bentonite, and kaolin, to a hard capsule film.
Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).
Abstract: Described herein is the development of synthetic routes to produce a wide variety of substituted phenanthridines, specifically, multidentate phenanthridine-containing ligand frameworks capable of anchoring to Pt via more than one binding site and with the phenanthridinyl moiety co-planar to the coordination plane of Pt. The multidentate chelation is designed to attenuate the reactivity of the platinum complex in vivo, and ultimately help mitigate side effects. In addition, the geometry of phenanthridine binding to the metal centre is altered compared to in phenanthriplatin, thanks to the constraints of the ligand geometry. By enforcing coplanar binding with the metal's square planar coordination plane, these compounds exhibit altered modes of activity, and should hence enhance/change the spectrum of activity of our prodrug candidates compared with phenanthriplatin.
Type:
Grant
Filed:
May 24, 2019
Date of Patent:
April 19, 2022
Assignee:
University of Manitoba
Inventors:
David E. Herbert, Issiah B. Lozada, Bin Huang, Yaorong Zheng, Zihan Qiu
Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.
Type:
Grant
Filed:
September 30, 2019
Date of Patent:
April 12, 2022
Assignee:
Serina Therapeutics, Inc.
Inventors:
Randall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
Type:
Grant
Filed:
September 23, 2021
Date of Patent:
April 5, 2022
Assignee:
Ocular Therapeutix, Inc.
Inventors:
Charles D. Blizzard, Rami El-Hayek, Michael Goldstein, Peter Jarrett, Andrew Vanslette
Abstract: The present disclosure provides a carrier composition for eye drops in which a substance to be delivered is loaded in a carrier, wherein the substance to be delivered includes one or more selected from the group consisting of an anti-inflammatory agent, a glaucoma treatment agent, a calcium channel blocker (CCB), an NMDA-receptor blocker, an antioxidant, a nitric oxide synthase inhibitor, a heat shock protein (HSP), a cystinosis treatment agent, and an antibiotic, the carrier has a spherical shape, the carrier includes a multilayer shell in a region ranging from the center to the surface of the carrier, the multilayer shell includes a core located in the center of the carrier and including a carboxymethyl cellulose (CMC)-based hydrogel having a degree of substitution (D.S.) of 0.9, a first shell located on the surface of the core and including a CMC-based hydrogel having a degree of substitution of 0.
Type:
Grant
Filed:
December 27, 2019
Date of Patent:
March 1, 2022
Assignee:
HYUNDAIBIOSCIENCE Co., Ltd.
Inventors:
Young Joo Jun, Ji Hyun Kim, Byung Woo Yoo, Ji Young Choi
Abstract: Medical devices with a hydrogel layer covalently attached to a portion of the outer surface of the medical device are provided along with methods for applying the coating. The hydrogel layer can include a first polymer species comprising polyethylene glycol (PEG) and a second polymer species. Examples of the second polymer species include PEG and polyacrylamide (PAM). The first and second species can be at least partially cross-linked. Methods for forming the hydrogel coatings on the medical devices are provided including nucleophilic conjugate reactions, such as Click reactions.
Type:
Grant
Filed:
December 24, 2019
Date of Patent:
March 1, 2022
Assignee:
Tangible Science, Inc.
Inventors:
Karen Havenstrite, Victor W. McCray, Brandon M. Felkins, Paul Cook
Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.
Type:
Grant
Filed:
January 24, 2020
Date of Patent:
February 22, 2022
Assignee:
OSI Pharmaceuticals, LLC
Inventors:
Stanley C. Gill, Kenneth K. Iwata, Gregory J. Riely, Jun Wu, Helena Yu
Abstract: In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles.
Type:
Grant
Filed:
July 12, 2018
Date of Patent:
February 1, 2022
Assignee:
Varian Medical Systems, Inc.
Inventors:
Hongxia Zeng, Bruce R. Forsyth, Hong Cao, Matthew R. DeWitt, Heidi Schwanz
Abstract: The present application discloses dual-function starch-based composite nanoparticles as well as a preparation method and application thereof. The preparation method comprises: hydrolyzing starch to form linear dextrin, grading the linear dextrin by using an alcohol-alcohol gradient precipitation method to obtain linear dextrin having homogeneous molecular weight distribution; oxidizing the linear dextrin by adopting an oxidation system to obtain oxidized dextrin; carrying out complex reaction on the oxidized dextrin and curcumin to form an oxidized dextrin-curcumin complex; and forming an oxidized dextrin-curcumin/chitosan hydrochloride composite nanoparticles from the oxidized dextrin-curcumin complex and chitosan hydrochloride. The aqueous phase solution of the dual-function starch-based composite nanoparticles containing gel polysaccharide is uniformly mixed with primary emulsion, calcium ion induction is carried out on the obtained double emulsion to obtain double-emulsion gel.
Type:
Grant
Filed:
January 13, 2020
Date of Patent:
December 21, 2021
Assignee:
HEFEI UNIVERSITY OF TECHNOLOGY
Inventors:
Bao Zhang, Baocai Xu, Xiaomin Li, Peijun Li, Yi Pan, Ran Meng, Xiaolong Li, Wenjie Liu
Abstract: Disclosed herein are disintegrin variants, and methods for suppressing or inhibiting platelet aggregation in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of the present disintegrin variant to alleviate or ameliorate symptoms associated with diseases, disorders, and/or conditions resulted from platelet aggregation. According to preferred embodiments, the present disintegrin variant is applied as a coating on an implantable device, such as a stent or a catheter.
Type:
Grant
Filed:
August 9, 2017
Date of Patent:
December 21, 2021
Assignees:
NATIONAL TAIWAN UNIVERSITY, NATIONAL CHENG KUNG UNIVERSITY, DCB-USA LLC
Abstract: The invention provides liquid injectable copolymers of TMC and HTMC that are degradable in vivo. Degradation can be tailored by adjusting the amount of HTMC in the copolymer, the initial molecular weight of the copolymer, and the characteristics of the initiator used in its preparation. Specifically, the degradation rate increases as the amount of HTMC incorporated into the copolymer increases, as the molecular weight of the copolymer decreases, and as the hydrophobicity of the initiator decreases. Moreover, the degradation yields products such as glycerol and carbon dioxide that are non-toxic in vivo, and which will not cause a substantive change in tissue pH upon implantation in vivo. The copolymers may be used in applications such as drug delivery and as coatings.
Type:
Grant
Filed:
November 7, 2018
Date of Patent:
December 14, 2021
Assignee:
Queen's University at Kingston
Inventors:
Sara Mohajeri, Brian G. Amsden, Fei Chen
Abstract: A pharmaceutical composition is described. The composition may include: (i) a drug component including at least one pharmaceutically acceptable salt of glycopyrrolate; and (ii) a propellant component including 1,1-difluoroethane (HFA-152a).
Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Abstract: Compositions and methods for reducing the symptoms of skin conditions associated with the nail and surrounding tissue are provided. A medicated pad for cleaning and treating the nail and surrounding tissue is described, wherein said pad is saturated with a therapeutic composition comprising certain botanicals, an antimicrobial agent, a surfactant, and a moisturizing agent. The skin and nail conditions can include fungal infections of the nails. Kits for treating fungal infections of the nails are likewise described. Optionally, the kit may include a hydrating composition which includes shea butter, aloe, vitamins, arnica, emu oil, urea, and Vitamins C, A, E, and D. A bandage comprising a therapeutic pad instilled with an antifungal agent is also provided.
Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.
Type:
Grant
Filed:
February 5, 2021
Date of Patent:
November 2, 2021
Assignee:
Applied Molecular Transport Inc.
Inventors:
Derek Maclean, Randall J. Mrsny, Kevin Yin, Tahir Mahmood, Bittoo Kanwar, Sally Postlethwaite, Weijun Feng, Sean Dalziel, Hyojin Kim, Rajendra Tandale, Marvin Garovoy, John Koleng
Abstract: Ooids, microabrasive compositions containing ooids and methods of making microabrasive compositions containing ooids are described. Generally, ooids represent small particles, which are selectable for size, size distribution, and other characteristics and can be used as a microabrasive particle. Ooids generally show a high level of symmetry, sphericity, roundness and a low aspect ratio. As described here, these characteristics generally yield a predictable and highly effective abrasive.
Type:
Grant
Filed:
September 6, 2019
Date of Patent:
October 26, 2021
Assignee:
California Institute of Technology
Inventors:
Elizabeth J. Trower, Usha F. Lingappa, John P. Grotzinger, Woodward Fischer
Abstract: The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 ?m.
Abstract: Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.